from the quickly evolving field of oncology analysis, precise and economical mutation screening is very important for acquiring targeted therapies. The KRAS providers Platform plays a pivotal part Within this landscape by giving thorough methods for KRAS mutation profiling and analysis. KRAS mutations, found in about 95% of RAS-relevant oncogenic a